NovoCure Ltd (NASDAQ:NVCR)
| Market Cap | 1.71B+21.8% |
| Revenue (ttm) | 725.39M+12.9% |
| Net Income | -121.73M+31.5% |
| EPS | -1.06+34.2% |
| Shares Out | 116.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,647,780 |
| Open | 14.00 |
| Previous Close | 13.43 |
| Day's Range | 13.91 - 14.94 |
| 52-Week Range | 9.82 - 21.45 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 26.00(+77.96%) |
| Earnings Date | Feb 25, 2027 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating NVCR in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
Ask Barron about NVCR
$NVCR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NVCR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NVCR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NVCR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NVCR Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NVCR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NVCR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NVCR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $56.00M |
| VBVanguard Morningstar Small-Cap ETF | $39.73M |
| IWMiShares Russell 2000 ETF | $36.84M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $22.12M |
| VXFVanguard Extended Market ETF | $19.31M |
| IWOiShares Russell 2000 Growth ETF | $12.51M |
Estimated from each fund’s disclosed top holdings × AUM
NVCR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NVCR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Healthcare: 51 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 66.9
What’s Behind the Score
News check: Regulatory approval for Optune Pax in Japan is a concrete positive catalyst; financial results announcement is neutral procedural news; valuation opinion pieces are underweighted per guidance.